High blood triglycerides: a plain-language guide

High blood triglycerides, known medically as hypertriglyceridemia, means there is too much of a particular type of fat in the blood, which at mild levels adds to the risk of heart and blood vessel disease and at very high levels can cause sudden inflammation of the pancreas [2].

This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.

Key facts

  • Triglycerides are the main type of fat in the blood. Some come from food, and the liver makes its own supply [6].
  • This page is about triglycerides specifically, not cholesterol. The two are different fats, they are measured on the same blood test, and they are treated differently [6,2].
  • About one quarter of United States adults aged 20 and over had a triglyceride level of 150 mg/dL or more when measured in a national survey between 2009 and 2012 [1].
  • Mild and moderately raised levels usually cause no symptoms at all and are found on a routine blood test [1,6].
  • Very high levels carry a real risk of acute pancreatitis, a sudden and serious inflammation of the pancreas that needs hospital treatment [3,7].
  • Treatment starts with finding and treating the underlying cause. Medicines include fibrates, prescription omega-3 preparations and, since 2024, two new injected medicines for the most severe forms [2,12,13].

On this page

What are high blood triglycerides?

Triglycerides are the main type of fat in the blood and the body’s main store of energy. Some come from food, and the liver makes the rest [6]. Hypertriglyceridemia is the medical name for having too much.

How this differs from high cholesterol. Both are fats and both appear on the same blood test, though they are not the same thing. Cholesterol builds cell walls and makes hormones. Triglycerides are stored fuel. They have different causes and different treatments, which is why this page covers triglycerides alone. For the wider picture, see the trialport guide to dyslipidemia.

The severity levels. The Endocrine Society sorts fasting results into bands, since a slightly raised level and an extremely high one are different problems [2]:

Band mg/dL mmol/L
Normal below 150 below 1.7
Mild 150 to 199 1.7 to 2.3
Moderate 200 to 999 2.3 to 11.2
Severe 1,000 to 1,999 11.2 to 22.4
Very severe 2,000 or more 22.4 or more

Mild and moderate levels matter mainly for the heart and blood vessels, severe and very severe levels for the risk of pancreatitis [2]. Other organizations differ: several treat 500 mg/dL and above as severe, and United Kingdom guidance uses mmol/L [3,12,5].

How common is it?

Raised triglycerides are common. About one quarter of United States adults aged 20 and over had a level of 150 mg/dL or more in a national survey covering 2009 to 2012 [1]. That counts people tested in a survey, not people given a diagnosis. Raised levels affect 10 to 20 percent of United States children and adolescents [9].

Severe levels are far less common. A 2025 review pooling studies from several countries found roughly 1 in 88 adults above 500 mg/dL and 1 in 556 above 1,000 mg/dL, higher in the United States and China than in Europe. Guidelines disagree about where severe begins, and good data are missing for most of the world [15]. Familial chylomicronemia syndrome has been estimated at about 1 in 300,000, and far higher in parts of Quebec, though estimates vary [11,10].

What causes it?

Levels rise when the body makes more triglycerides than it clears [6].

Inherited causes. A gene is an instruction inside a cell, and a gene variant is a change in that instruction. Familial chylomicronemia syndrome is the severe genetic form, caused by changes in both copies of LPL, APOC2, APOA5, LMF1 or GPIHBP1. That pattern is called autosomal recessive: a person needs a changed copy from each parent, and carrier parents usually have no symptoms. Multifactorial chylomicronemia syndrome is much more common, where small inherited susceptibilities combine with a trigger such as diabetes, alcohol or a medicine [11]. Familial combined hyperlipidemia raises triglycerides too [2]. Treatment differs, so telling these apart is important [3].

Other causes. These include uncontrolled diabetes, chronic kidney disease, an under-active thyroid, liver disease, pregnancy and metabolic syndrome [2,6]. Alcohol raises triglycerides, and some people are sensitive to small amounts [6]. So do several prescribed medicines, including some diuretics, beta blockers, steroids, oral estrogen and isotretinoin [2,3]. Never stop one on your own. Ask the prescriber.

What are the symptoms?

Mild and moderately raised triglycerides usually cause no symptoms, and turn up on a blood test done for another reason [1,6].

Very high levels can cause visible signs [10,11]:

  • small yellow fatty lumps under the skin, called eruptive xanthomas
  • an enlarged liver and spleen
  • blood that looks milky when it is drawn
  • a pale pink appearance at the back of the eye
  • tummy pain

Difficulties with mood, memory and thinking are reported in the familial form. That form shows early in children, about a quarter before their first birthday. Pregnancy raises triglycerides and, in the familial form, the risk of pancreatitis, so it is monitored closely [11].

When to seek urgent help. Very high triglycerides can trigger acute pancreatitis, which needs hospital treatment. Ask for an urgent doctor’s appointment, or contact your local urgent care service, if you get sudden severe tummy pain that does not go away, especially with a high temperature or shivering. Call emergency services or go to an emergency department if that pain spreads to your back, or comes with lasting bloating, a fast heartbeat, difficulty breathing, or bruised-looking skin around the belly button [7].

How is it diagnosed?

Triglycerides are measured with a simple blood test, usually part of a lipid panel that also reports cholesterol [6]. Most people start with a family doctor, and move to a specialist lipid clinic where levels are very high or a genetic cause is suspected [5].

Fasting or not. The Endocrine Society recommends a fasting sample, after 12 hours, for making the diagnosis [2]. United Kingdom guidance no longer requires fasting for routine testing, and HEART UK suggests aiming below 2.0 mmol/L non-fasting or 1.7 mmol/L fasting [6]. Above 1,000 mg/dL a fasting sample is not needed [11]. So it is often fasting, not always, and the team will say which they want. Two results weeks apart are advised before starting a triglyceride medicine [3].

The next step is looking for a cause: blood sugar, thyroid, kidney and liver tests, a review of current medicines, and questions about alcohol [2]. Genetic testing can confirm the familial form [11]. Diagnosis is often delayed, since mild and moderate levels cause nothing a person would notice, and the familial form is repeatedly mistaken for unexplained pancreatitis [11]. English guidance asks for specialist advice above 10 mmol/L and urgent review above 20 mmol/L [5].

How is it treated?

The goal differs by level: reducing heart and blood vessel risk at mild and moderate levels, and preventing pancreatitis at severe levels. The first step is treating the cause, whether that is blood sugar, an under-active thyroid, kidney or liver disease, or a medicine [2].

Food, alcohol and activity. Guidelines call these the foundation of care, with a registered dietitian giving individual advice rather than general rules. Alcohol is limited, and stopped where levels are markedly raised. Activity is encouraged, and weight is discussed with the care team [3]. Where levels are severe a strict low-fat plan is prescribed and monitored, with total fat often kept to 20 grams a day or less [11]. None of this is anyone’s fault.

Fibrates. Where there is a risk of triglyceride-related pancreatitis, a fibrate such as fenofibrate is the recommended first medicine [2].

Prescription omega-3. These are not shop-bought fish oil, and supplements are no substitute. One purified form, icosapent ethyl, cut major cardiovascular events by 25 percent in the REDUCE-IT trial, with more atrial fibrillation and bleeding than placebo [3].

Statins. Statins mainly lower cholesterol and remain the foundation of treatment for heart and blood vessel risk where triglycerides stay high. They lower triglycerides only modestly and are not used alone for severe levels [1,2,8].

Newer targeted medicines. Volanesorsen is authorized in Europe, though not in the United States, for genetically confirmed familial chylomicronemia syndrome [4]. Olezarsen, a monthly injection, was approved in the United States in December 2024 for that condition, and in June 2026 for severe hypertriglyceridemia to lower the risk of acute pancreatitis [12]. Plozasiran, given every three months, was approved there in November 2025 for the familial form [13]. There is no cure, and availability differs greatly between countries.

Living with high blood triglycerides

For most people this is a number followed over years alongside blood pressure and cholesterol. Where levels are severe, monitoring is closer, and in the lipoprotein lipase form fasting triglycerides are usually checked every three months. Several things are worth discussing in advance in that form, including alcohol, oral estrogen, diuretics, isotretinoin, steroids, beta blockers and fish oil supplements. Bring that list to whoever prescribes. Close relatives are advised to have a lipid blood test, and family planning is a conversation to have early [11].

An emergency plan helps: know the warning signs of pancreatitis, keep a written note of the diagnosis and current medicines, and agree who to call out of hours. The toll of repeated hospital visits and a strict eating plan is recognized in the severe forms rather than imagined [11].

Thinking about a clinical trial?

Clinical trials test whether a treatment works and is safe. Triglycerides are an active research area, so studies come up reasonably often. Deciding whether to look into one is personal, and it helps to take it in steps.

1. Understand what the study is asking

It is worth being clear on what a study involves:

  • what the researchers are trying to learn
  • what is being studied, and what it is compared with
  • how long it lasts, since lipid studies often run a year or more
  • what visits and tests are involved, including repeated fasting blood tests
  • the possible benefits, and the known and unknown risks
  • what happens when the study ends

2. Consider possible medical suitability

Every trial has rules about who can take part, called eligibility criteria. For a triglyceride study, they might include a fasting level inside a set range confirmed on two samples weeks apart, a stable statin dose beforehand, blood sugar under reasonable control, no recent acute pancreatitis, a genetic result or clinical score confirming familial chylomicronemia syndrome, and reliable contraception for some medicines.

trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.

Explore high blood triglycerides clinical trials through trialport

3. Consider whether participation fits your life

A study can look right on paper and still be hard in practice. Worth thinking through:

  • the time each visit takes, and how many there are across a long study
  • fasting before appointments, and how that fits around work, school or caring for others
  • travel, distance and who would come along
  • how you feel about injections, or about a strict eating plan set by the study
  • support from family and friends, and whether you understand the study well enough to decide

trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.

4. Ask questions before deciding

Useful questions to put to a research team:

  • Why is this study being carried out, and what is already known?
  • What exactly would I need to do, and for how long?
  • What are the known risks, and what is still unknown?
  • Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly. Would I keep my usual lipid treatment alongside it?
  • How many blood tests are there, and will the study set my diet?
  • Can I leave after joining, and what happens if I do?
  • Who looks after my usual care, and who do I contact if I feel unwell at night or on a weekend?
  • Could I keep receiving the treatment afterward, and are travel costs covered?

Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.

Search for clinical trials at app.trialport.com.

Current research

Most recent movement has come from medicines that switch off a single gene’s message in the liver.

  • APOC3. This protein slows the clearance of triglycerides. Three medicines that lower it are now authorized somewhere: volanesorsen in Europe, olezarsen and plozasiran in the United States [12,13]. European guidance notes that injected treatments aimed at APOC3 can lower triglycerides by up to 80 percent [4].
  • ANGPTL3. This protein blocks the enzymes that break triglycerides down. Zodasiran lowered triglycerides by 51 to 63 percentage points more than placebo at 24 weeks in a study of 204 adults, with a temporary rise in blood sugar markers at the highest dose [14]. It is not approved for hypertriglyceridemia.
  • Open questions. Whether lowering triglycerides prevents heart attacks is unsettled. Fibrates have not shown clear benefit on top of a statin [4].

Study status checked: 3 August 2026. Research moves quickly and what is studied changes, so this list will date. For current information, search at app.trialport.com.

Support and further information

In the United Kingdom, HEART UK is the national cholesterol and blood fats charity, with a clear triglycerides section on causes, targets and treatment [6]. The NHS page on acute pancreatitis sets out the warning signs [7].

In the United States, the National Lipid Association’s patient site LearnYourLipids explains triglycerides and testing plainly, and can help locate a lipid specialist [16]. The FCS Foundation is the organization for familial chylomicronemia syndrome, run for and with affected families [17].

Coverage elsewhere is thin. Most countries have a general heart charity rather than anything specific to triglycerides, and there is little material in languages other than English. Where no local group exists, a national heart or lipid association, or the treating clinic, is the best starting point.

Questions people often ask

Is a high triglyceride result serious?
It depends how high. Mild and moderate levels add to long-term heart risk without symptoms. Levels above roughly 500 mg/dL bring a risk of pancreatitis [2,3].

Are triglycerides the same as cholesterol?
No. Both are fats measured on the same blood test, though they do different jobs and are treated differently [6].

Do I need to fast before the test?
Often, though not always. A fasting sample is preferred for the diagnosis, while United Kingdom guidance no longer requires fasting for routine testing. Follow whatever your clinic asks [2,5,6].

Can high triglycerides be inherited?
Yes. The severe familial form needs a changed copy of the same gene from each parent, and relatives are advised to be tested [2,11].

Do fish oil capsules from a shop help?
Guidelines advise prescription-strength omega-3 instead, and in the lipoprotein lipase form supplements are avoided because they can raise levels [3,11].

Sources

  1. Carroll MD, Kit BK, Lacher DA. Trends in Elevated Triglyceride in Adults: United States, 2001-2012. NCHS Data Brief No. 198. National Center for Health Statistics, Centers for Disease Control and Prevention. May 2015. https://www.cdc.gov/nchs/products/databriefs/db198.htm Accessed 3 August 2026.
  2. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):2969-2989. doi:10.1210/jc.2011-3213. https://academic.oup.com/jcem/article/97/9/2969/2536709 Accessed 3 August 2026.
  3. Rubenfire M. ACC Consensus on ASCVD Risk Reduction in Hypertriglyceridemia: Key Points. American College of Cardiology, 28 July 2021, summarizing Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. Journal of the American College of Cardiology. 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2021/07/27/21/04/2021-acc-ecdp-hypertriglyceridemia Accessed 3 August 2026.
  4. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190. https://academic.oup.com/eurheartj/article/46/42/4359/8234482 Accessed 3 August 2026.
  5. National Institute for Health and Care Excellence. NICE guideline NG238, on cardiovascular disease risk and reduction including lipid modification: Recommendations. https://www.nice.org.uk/guidance/ng238/chapter/Recommendations Accessed 3 August 2026.
  6. HEART UK. Triglycerides. https://www.heartuk.org.uk/cholesterol/triglycerides Accessed 3 August 2026.
  7. National Health Service. Acute pancreatitis. https://www.nhs.uk/conditions/acute-pancreatitis/ Accessed 3 August 2026.
  8. American Heart Association. Top Things to Know: 2026 Guideline on the Management of Dyslipidemia, summarizing Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. Published online 13 March 2026. doi:10.1161/CIR.0000000000001423. https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know Accessed 3 August 2026.
  9. Peterson AL, Ashraf AP, Bachman J, et al. Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026;46(4):e000195. doi:10.1161/ATV.0000000000000195. https://pubmed.ncbi.nlm.nih.gov/41705332/ Accessed 3 August 2026.
  10. MedlinePlus Genetics, National Library of Medicine. Familial lipoprotein lipase deficiency. https://medlineplus.gov/genetics/condition/familial-lipoprotein-lipase-deficiency/ Accessed 3 August 2026.
  11. Burnett JR, Hooper AJ, Hegele RA. Lipoprotein Lipase Deficiency. In: GeneReviews. University of Washington, Seattle. Initial posting 12 October 1999, last update 23 July 2026. https://www.ncbi.nlm.nih.gov/books/NBK1308/ Accessed 3 August 2026.
  12. U.S. Food and Drug Administration. FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia. 24 June 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-shown-reduce-risk-acute-pancreatitis-adults-severe-hypertriglyceridemia Accessed 3 August 2026.
  13. Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS). Press release, 18 November 2025. https://arrowheadpharma.com/en-us/newsroom/arrowhead-pharmaceuticals-announces-fda-approval-redemplor Accessed 3 August 2026.
  14. Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine. 2024;391(10):913-925. doi:10.1056/NEJMoa2404147. https://pubmed.ncbi.nlm.nih.gov/38809174/ Accessed 3 August 2026.
  15. Baass A, Paquette M, Lam O, Hofer K, Collet J, McClain MR. Prevalence, incidence, and definition of severe hypertriglyceridemia: A comprehensive review and weighted summary. Journal of Clinical Lipidology. 2025;19(6):1550-1563. doi:10.1016/j.jacl.2025.08.012. https://pubmed.ncbi.nlm.nih.gov/41073238/ Accessed 3 August 2026.
  16. National Lipid Association. Triglycerides. LearnYourLipids patient education. https://www.learnyourlipids.com/lipids/triglycerides/ Accessed 3 August 2026.
  17. FCS Foundation. Living with familial chylomicronemia syndrome. https://livingwithfcs.org/ Accessed 3 August 2026.

Review information

Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026

Related Posts